Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease

NCT06709014 is registered in ClinicalTrials.gov with Annovis Bio Inc. as lead sponsor.

NCT NCT06709014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06709014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease
Lead sponsor
Annovis Bio Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 4, 2025
Completion date
June 30, 2028
Enrollment
760 (estimated)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

early alzheimers disease